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Background: US-based trials have shown that Multidimensional Family Therapy (MDFT) not only reduces substance
abuse among adolescents, but also decreases mental and behavioural disorder symptoms, most notably
externalising symptoms. In the INCANT trial, MDFT decreased the rate of cannabis dependence among Western
European youth. We now focus on other INCANT outcomes, i.e., lessening of co-morbidity symptoms and
improvement of family functioning.
Methods: INCANT was a randomised controlled trial comparing MDFT with individual therapy (IP) at and across
sites in Berlin, Brussels, Geneva, The Hague, and Paris. We recruited 450 boys and girls aged 13 up to 18 years with
a cannabis use disorder, and their parent(s), and followed them for 12 months. Mental and behavioural
characteristics (classified as ‘externalising’ or ‘internalising’) and family conflict and cohesion were assessed.
Results: From intake through 12 months, MDFT and IP groups improved on all outcome measures. Models
including treatment, site, and referral source showed that MDFT outperformed IP in reducing externalising
symptoms.
Adolescents were either self-referred to treatment (mostly on the initiative from people close to the teen) or
referred under some measure of coercion by an external authority. These two groups reacted equally well to
treatment.
Conclusions: Both MDFT and IP reduced the rate of externalising and internalising symptoms and improved family
functioning among adolescents with a cannabis use disorder. MDFT outperformed IP in decreasing the rate of
externalising symptoms. Contrary to common beliefs among therapists in parts of Western Europe, the ‘coerced’
adolescents did at least as well in treatment as the self-referred adolescents.
MDFT shows promise as a treatment for both substance use disorders and externalising symptoms.
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Why INCANT?
In 1999, the (junior) Ministers of Health of five Western
European countries – Belgium, France, Germany, the
Netherlands, and Switzerland – concluded that their coun-
tries were fighting each other over cannabis policies with-
out sufficient evidence to support any view. Among other
things, they decided to fund a transnational trial – named
INCANT (INternational CAnnabis Need for Treatment) –
to test an outpatient treatment of cannabis use disorder
among youth who frequently have co-occurring problems.
The treatment selected was Multidimensional Family
Therapy (MDFT), which has been developed from 1985 on-
wards by Liddle and co-workers mainly at the Center for
Treatment Research on Adolescent Drug Abuse (CTRADA),
University of Miami Miller School of Medicine. MDFT is
a family based outpatient treatment programme for ado-
lescent problem behaviour targeting major domains in the
life of an adolescent. The life domains include the youth
him- or herself, parent(s), family, friends and peers, school
and work, and leisure time. MDFT views family func-
tioning as instrumental in creating new, developmentally
adaptive lifestyle alternatives for the adolescent. MDFT
has been tested with success in different adolescent popu-
lations, doses and treatment delivery settings [1,2].
The history, design, baseline data, and primary (cannabis
use related) outcomes of INCANT have been described
before [3-5]. Across our research sites in the five Western
European countries mentioned, cannabis use disorder was
responsive to treatment. Relative to comparison treat-
ment, MDFT was superior in decreasing the prevalence of
cannabis dependence, and excelled in reducing the fre-
quency of cannabis consumption in youth with most se-
vere cannabis use [5].
Secondary outcomes
We now report on other outcomes of INCANT, i.e., effects
on co-morbid mental and behavioural symptoms and on
family functioning. We call these outcomes ‘secondary’, not
because they are of minor importance, but because the pri-
mary focus of INCANT was to establish treatment effects
on cannabis use variables. In line with previous MDFT re-
search [1,2], we assumed MDFT would be effective in redu-
cing mental and behavioural co-morbidity – internalising
and externalising symptoms – in our adolescent cannabis
abusing trial participants, while also improving family
functioning. Teenagers with internalising symptoms are at
increased risk of developing anxiety disorders (symptoms
such as feeling nervous, fearful, timid) and mood disorders
(symptoms such as feeling lonely, unloved, unhappy, wor-
ried, inferior). Externalising symptoms (e.g., arguing, being
mean or destructive, getting into fights, stealing, setting
fires) are associated for instance with conduct disorder
and delinquency [6].Interactions between substance use, co-morbidity and
family factors have been outlined before. In children and
adolescents, externalising symptoms and disorders may
foreshadow initiation and progression of later cannabis
use [7-10], and are associated with an increased risk of
later cannabis and other substance dependence [11]. The
influence of internalising symptoms on these measures
is less clear [12,13]. Family- and peer-related factors may
also predict later cannabis use. When family cohesion is
low, a teen is more likely to start using cannabis [14],
and family conflict may decrease the success of cannabis
treatment in adolescents [15]. Poor family functioning is
a shared risk factor for cannabis use and mental disor-
ders in adolescents [16]. In a prospective study, externalising
symptoms and family dysfunctioning jointly correlated with
a higher risk of developing substance use disorders during
adolescence [17]. In other words, externalising symptoms
(perhaps also internalising symptoms), poor family func-
tioning, and cannabis use are interrelated phenomena.
Thus, a treatment programme like MDFT may reduce
cannabis use (problems) along at least two pathways,
i.e., through a direct effect on cannabis use, and indirectly
by decreasing the impact of co-morbidity and/or family
factors. As for the indirect influences, MDFT generally was
more effective than cognitive behavioural therapy (CBT)
and other active comparison treatments in decreasing both
internalising symptoms and externalising symptoms and
behaviours [18-20]. If the therapist focuses his or her atten-
tion not just on the adolescent but also on the family, this
may result in better substance use and externalising/inter-
nalising treatment outcomes [21]. We know from recent
studies that MDFT reduces cannabis use most strongly in
adolescents who have the most severe problems (severity
in these studies is defined as heavy drug use or a combin-
ation of heavy drug use and more extensive comorbidity
including family dysfunction) [5,22,23].
Objectives
We examined if MDFT had positive effects in adolescents
on comorbid mental and behavioural symptoms and on
family functioning. We assumed that MDFT would be
more effective than the comparison treatment (individual
psychotherapy; IP) in reducing the rate of externalising
(more so than internalising) symptoms.
Methods
Design
INCANT was a phase III(b) randomised controlled effect-
iveness trial with an open-label, parallel group design,
comparing MDFT with individual psychotherapy (IP)
across sites in five Western European countries. Study
sites started the 24-month recruitment phase between
July 2006 and February 2007. Assessments were sched-
uled at baseline and at 3, 6, 9 and 12 months thereafter.
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countries [3].
Participants
Eligible participants were teens between the ages of 13
and 18 years from both genders with a cannabis use dis-
order (dependence or abuse) established as having been
present within the year prior to baseline. At least one
parent had to take part in the treatment.
Adolescents were ineligible if they suffered from a
current mental disorder or condition requiring inpatient
treatment (e.g., psychosis, advanced eating disorder, sui-
cidal ideation), or had a substance use disorder requiring
maintenance treatment with methadone or buprenor-
phine. Cases were excluded if the adolescent and/or par-
ent were unable to speak and read the local language.
We consecutively recruited 450 cases/families, with 60 to
120 cases/families per site depending on the local budget
available [5].
The referral source for the adolescents varied [4]. We
distinguished two classes of referral. Self-Determined
(SD) referral applied to adolescents who took the initia-
tive to contact the treatment site on the advice (with no
obligation) of relatives, friends, acquaintances, school, and
occasionally on their own initiative. Externally Coerced
(EC) referral applied to adolescents who felt they could not
refuse treatment out of fear of sanctions, such as being
kicked out of something (school, services, or programmes),
being placed out of home, or being detained or otherwise
being sanctioned by Justice authorities. This included refer-
ral by youth probation officers or appointed family guard-
ians, public prosecutors, or court.
Study sites; randomisation
Sites were selected from addiction, youth and forensic
care centres upon nomination by Government officials,
after site visits by study staff, and on the basis of per-
formance in a pilot study [3]. The sites were (a) the out-
patient cannabis clinic of the department of psychiatry
of Brugmann University Hospital in Brussels, (b) Thera-
pieladen in Berlin, (c) Centre Emergence in Paris with
suburban CEDAT (Conseils Aide et Action contre le
Toximanie) sub-sites in Mantes la Jolie and St Germain
en Laye, (d) the twin sites of Parnassia Brijder (addiction
care) and De Jutters (forensic care) in The Hague, and
(e) Phénix in Geneva. All sites were youth oriented [5].
Concealed randomisation took place per site, using
three stratification variables (gender, age and frequency
of cannabis consumption) [3], right after the case had
been found eligible at the baseline assessment. For each
stratum, the database computer generated 50 independ-
ent randomisations [5].
The database automatically assigned a code to each
new case entered by a research assessor and informedher about the allocated treatment, independently from
any trial staff [3,5].
Therapists and interventions
Different therapists from the same site delivered either
MDFT or IP. They were similar in age, gender, education
and experience [24]. Training procedures for MDFT
therapists have been described before [24], and included
a two weeks course in using the treatment manual, site
visits, and active supervision during the study regarding
session planning, case assessment and developing the
treatment plan. Moreover, a sample of recordings of ses-
sions were independently reviewed on measures of treat-
ment adherence and competence [24]. For IP, procedures
for intervision and supervision were already in place, and
where these were found wanting, they were upgraded to
the level required for the study.
An average of two MDFT sessions per week was pre-
scribed – in roughly equal proportion to be held with
the adolescent, parent, and family (adolescent and parent
together), respectively. Sessions could take place at the
office of the therapist, the family’s home, or any other lo-
cation. IP was to last as long as MDFT (6 months), but
with fewer sessions per week. Details on the actual treat-
ment dose received have been reported before [24].
IP was individual counselling of the adolescent, which
was treatment as usual across sites. IP was not standar-
dised across sites; this would have required a revolution
in deeply rooted treatment practices and would have
aroused opposition from professional societies and other
stakeholders – a challenge well beyond our capabilities. IP
varied from full CBT in The Hague [23] and Brussels to
more elective approaches in the other countries. MDFT
and IP were comparable in terms of motivational inter-
viewing, intervision (peer consulting), administrative and
referral procedures, and drug education [5,24].
Outcome measures
Cannabis use was assessed with the Timeline Follow-Back
method (TLFB), a well-validated self-report method to
record frequency of cannabis use as adapted for adoles-
cents [25]. The TLFB registers daily cannabis use for the
90 days preceding the assessment, using a calendar and
other memory prompts.
Also, urine samples were taken but these data were in-
complete in Switzerland, where many clinicians regard
urine testing as breaching the personal integrity of clients.
This was already expected, and accepted as unchangeable,
at the time the trial was designed. The laboratory results
are not reported here.
Adolescents’ internalising and externalising symptoms
were recorded with the Youth Self Report (YSR). This in-
strument is reliable and valid across a variety of studies,
populations, and languages (including Dutch, German and
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and externalising symptoms of their children, the parent
version of the YSR, called the CBCL (Child Behaviour
Checklist), was used [28]. The data used were from the
parent most directly involved in raising the adolescent as
established at baseline or from the parent volunteering
to contribute to all follow-up assessments. The YSR and
CBCL were scheduled at baseline and at six and twelve
months.
We used the Anxiety/Depression, Withdrawn, and
Somatic complaints sub-scales of the YSR and CBCL as
components of the Internalising symptoms scale of the
YSR and CBCL, which has been validated [29]. A high
score on this scale means that the adolescent (or in the
CBCL, the parent) reported a high rate of internalising
symptoms. For externalising symptoms, we used another
validated scale, based on the sub-scales Delinquency and
Aggressive behaviour [29]. There is only one question on
substance use in the YSR and CBCL among the 30 YSR
externalising symptoms items, so overlap between our pri-
mary and secondary outcome measures was negligible.
Family conflict and cohesion were assessed with the
respective sub-scales from the Family Environment Scale
(FES), a widely used and well-validated self-report meas-
ure [30], which was completed by the teen. The FES was
delivered at baseline and at six, nine and twelve months.
With a single exception, YSR, CBCL and FES analyses
reported here are across-site. Information on outcomes
per site has been published before [31].
Analyses
We followed an intent-to-treat approach, with change in
the YSR, CBCL, and FES outcomes (assessed at intake, 6,
9 [FES only], and 12 months) analysed using latent growth
curve modelling (LGC; [32]) conducted with the software
Mplus ([33], version 6). Both intercept and slope were
modelled separately for each outcome. We included site
and referral source (self-directed or externally coerced re-
ferral) as covariates, based on INCANT’s baseline findings
[4], along with treatment condition. Site by treatment in-
teractions were not statistically significant and therefore
were omitted from the final models. Missing data were
handled with full information maximum likelihood esti-
mation, under the missing at random assumption [34].
A statistically significant (p < 0.05) slope parameter, as
tested by the pseudo-z test, indicated the intervention
was effective. For each slope intercept, we provide the 95%
confidence interval (CI). In conditional models, MDFT
was coded as 0 and IP as 1; thus, positive slope coefficients
associated with treatment would indicate greater decreases
in internalising and externalising problems for youth re-
ceiving MDFT. In addition, the magnitude of the coeffi-
cient indicated deviation from the mean slope associated
with MDFT [32].For comparing sites on continuous data we used ana-
lysis of variance (ANOVA).
Results
Sites varied on some baseline measures, as reported be-
fore [4,31]. As for measures to be used in the analysis of
secondary outcomes, the between-site difference in YSR
self-report of externalizing symptoms was most notable
(ANOVA; F [4, 425] = 6.4, p < 0.001). Youth in Germany
reported higher levels of externalizing symptoms than
youth in France and the Netherlands. Differences on other
baseline measures were negligible. Within sites, there
were no baseline discrepancies between the two treat-
ment arms.
Study dropout was low with, across-site, 90% of cases
completing the 12-month follow-up in the MDFT group
and 89% in the IP group [5].
LGC modelling
Table 1 shows the means and standard deviations for
each secondary outcome measure at each assessment
wave (baseline, 6 and 12 months for YSR and CBCL;
and baseline, 6, 9 and 12 months for FES). From base-
line through 12 months, across sites and treatments
and across the assessment points mentioned for the vari-
ous questionnaires, adolescents improved on all secondary
outcome variables: YSR-internalising slope = -0.80, 95%
CI = -1.02 to -0.58, pseudo-z = -6.74, p < 0.001; YSR-
externalising slope = -2.46, 95% CI = -2.86 to -2.06, pseudo-
z = -12.35, p < 0.001; CBCL-internalising slope = -1.60,
95% CI = -1.86 to -1.34, pseudo-z = -12.07, p < 0.001;
CBCL-externalising slope = -4.50, 95% CI = -5.08 to -3.92,
pseudo-z = -15.56, p < 0.001; FES-cohesion slope = 0.06,
95% CI = 0.04 to 0.08, pseudo-z = 12.00, p < 0.001; FES-
conflict slope = 0.06, 95% CI = 0.04 to 0.08, pseudo-z =
12.47, p < 0.001 (higher FES-conflict scores reflect less
conflict; therefore, a positive slope value means less
conflict). Table 2 lists the model parameters.
In most of these changes for the better, and at the
across-site overall level, MDFT and IP did equally well.
Running models including treatment condition pointed
to one measure where MDFT outperformed IP, i.e., the
decrease in self-reported (YSR) externalising problems
(slope coefficient on treatment = 1.00, 95% CI = 0.18 to
1.82, pseudo z = 2.45, p = 0.01, d = 0.26). This was not
reflected in the parents’ reports (CBCL): slope coeffi-
cient on treatment = 0.57, 95% CI = -0.55 to 1.69, pseudo
z = 1.02, p = 0.31.
The influence of referral
External coercion did not harm treatment outcome.
Across sites and treatments, SD and EC adolescents im-
proved to the same degree on secondary outcomes. EC
adolescents even showed greater improvement on the
Table 1 Observed sample sizes, means, and standard deviations for self- and parent-reported internalising
and externalising symptoms and for family functioning
Outcome measure Intake
M (SD)
6 Month
M (SD)
9 Month
M (SD)
12 Month
M (SD)
YSR Internalising n = 430 n = 346 n = 382
MDFT 14.59 (9.75) 10.96 (7.77) N/A 10.82 (8.87)
IP 14.60 (9.56) 11.99 (8.71) N/A 11.76 (9.23)
YSR Externalising n = 430 n = 346 n = 382
MDFT 21.57 (9.22) 17.08 (8.61) N/A 15.38 (9.07)
IP 19.73 (8.32) 17.12 (9.21) N/A 15.86 (8.80)
CBCL Internalising n = 433 n = 341 n = 363
MDFT 20.14 (10.32) 14.81 (9.75) N/A 13.08 (9.79)
IP 21.12 (11.18) 16.12 (10.90) N/A 13.96 (9.16)
CBCL Externalising n = 434 n = 341 n = 364
MDFT 26.25 (12.04) 18.44 (10.68) N/A 16.34 (11.15)
IP 23.84 (11.51) 18.76 (12.39) N/A 15.35 (9.80)
FES Conflicta n = 429 n = 345 n = 308 n = 357
MDFT 0.43 (0.21) 0.59 (0.22) 0.65 (0.15) 0.59 (0.20)
IP 0.45 (0.21) 0.62 (0.20) 0.67 (0.13) 0.63 (0.21)
FES Cohesion n = 429 n = 345 n = 308 n = 357
MDFT 0.63 (0.30) 0.83 (0.27) 0.80 (0.17) 0.85 (0.25)
IP 0.60 (0.29) 0.79 (0.27) 0.77 (0.18) 0.81 (0.26)
Note. Total sample was n = 450 adolescents. The table presents the number of cases (n) per outcome variable and assessment point on which the figures shown
are based. YSR = Youth Self-Report, MDFT =Multidimensional Family Therapy, IP = Individual psychotherapy, N/A = Not applicable, CBCL = Child Behaviour Checklist
(as completed by 1 parent), FES = Family Environment Scale.
aHigher scores reflect less conflict.
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on referral source = -1.54, 95% CI = -2.88 to -0.20, pseudo
z = -2.29, p = 0.02; d = 0.30).
Discussion and conclusions
MDFT and IP reduced youth-reported internalising and
externalising disorder symptoms and increased family
functioning (more cohesion, less conflict). This is not
just a reflection of ‘passage of time’ as MDFT outper-
formed IP in decreasing the rate of externalising, but not
internalising symptoms.
MDFT is often regarded as a substance abuse treat-
ment programme, for historic reasons (funding sources
and initial research interests) and achieved outcomes,
but the approach is also valuable for treating adolescent
externalising symptoms and delinquency. In teens, sub-
stance use frequently occurs along with a constellation
of other problems [35,36]. In earlier trials [18-20] and
the present one, MDFT reduced the rate of externalising
symptoms, more so than active comparison treatments.
Lowering the level of externalising symptoms may help
a youth to refrain from criminal offenses [35,36]. The
effect of treatment on externalising symptoms merits
further study in relation to the distal goal of reducing
criminal offenses.When we mounted INCANT, clinicians from espe-
cially Switzerland criticised our choice to also recruit
adolescents referred by Justice authorities. There is a
strong belief among some groups of therapists in Western
Europe that coercing a youth into treatment will harm the
chances of the therapist to establish a therapeutic alliance
with the adolescent, and for the treatment to be successful.
Our data did contradict this notion. Adolescents coerced
into treatment accepted therapy and stayed in therapy as
long as other teens [24]. Our findings show that these co-
erced adolescents did respond to treatment even better (on
the externalising symptoms measure) than other teens.
How to interpret this finding? There is older literature
on the effect of coerced treatment among detainees, but
reports on coerced referral in outpatient settings are scarce
and based on studies of limited quality. Nevertheless, it
would appear that coercion does not hurt and may even
improve outcomes [37].
Substance abuse treatment may lower the rate of inter-
nalising symptoms in adolescents, but the evidence is in-
consistent [1,5,7,8]. Our data confirm that treatment can
reduce the number of internalising symptoms. MDFT
did not differ from IP here.
We used well-tested and reliable self-report question-
naires [25-30]. YSR outcomes did not (fully) match CBCL
Table 2 Means and standard errors for growth factors
and phase differences on outcomes
Intercept Slope
M SE M SE
Parent-reported externalising
Growth factor mean 24.59*** 0.57 −4.50*** 0.29
Treatment comparison −1.79 1.12 0.57 0.56
Site comparison −0.03 0.53 −0.32 0.28
Referral source comparison 2.44 1.31 −1.54* 0.67
Parent-reported internalising
Growth factor mean 20.17*** 0.53 −3.48** 0.25
Treatment comparison 0.95 1.01 0.03 0.51
Site comparison −0.07 0.52 −0.13 0.24
Referral source comparison −0.72 1.25 −0.47 0.42
Youth-reported externalising
Growth factor mean 20.34*** 0.42 −2.46*** 0.11
Treatment comparison −1.52 0.84 1.00* 0.41
Site comparison −0.03 0.39 −0.11 0.20
Referral source comparison 0.39 0.98 0.31 0.49
Youth-reported internalising
Growth factor mean 14.07*** 0.45 −1.61* 0.20
Treatment comparison 0.19 0.89 0.52 0.44
Site comparison −0.15 0.37 −0.05 0.20
Referral source comparison 0.07 1.03 0.63 0.51
Family cohesion
Growth factor mean 0.64*** 0.02 0.06*** 0.01
Treatment comparison <0.01 0.04 −0.02 0.01
Site comparison 0.01 0.02 0.01 0.01
Referral source comparison <0.01 0.04 −0.01 0.02
Family conflict
Growth factor mean 0.49*** 0.02 0.06*** 0.01
Treatment comparison 0.04 0.03 <0.01 0.01
Site comparison <0.01 0.01 <0.01 0.01
Referral source comparison 0.01 0.03 <0.01 0.01
*p < .05, **p < .01, ***p < .001.
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YSR versus CBCL scores (different views of the adolescent
and the parent as to symptoms present) may signify higher
levels of psychopathology among the adolescents [39].
Both YSR and CBCL are valid as measured against clinic-
ally established diagnoses [40]. Yet, adolescents and their
parents may have different perceptions of what is going
on in the life of the teen. There are speculations about this
discrepancy in views, but a convincing explanation is still
wanting.
MDFT views the family as the prime environment to fa-
cilitate and strengthen treatment effects. Family conflictwill make it harder to positively respond to treatment
[1,2]. Our data confirm the importance of family conflict.
Teens from conflict-prone families benefitted more from
MDFT than from IP in reducing days of cannabis use.
There was no effect on the family conflict measure itself.
Possibly, our methods were not precise enough to meas-
ure changes in family functioning. The FES questionnaire
asks about the whole family, and specifically about the
teen - parent relationship.
Our study had limitations. One theory holds that
systems therapies such as MDFT increase parents’ compe-
tence, thus improving parental behaviour, and subse-
quently improving the behaviour of their child. Our study
did not include measures of parental behaviour, so we
cannot say if this chain of events did occur. However, a
detailed process study of another systems therapy (MST)
found evidence in support of the importance of these
intermediate steps in the link between treatment and
outcomes [41].
We recruited adolescents from widely varying back-
grounds and different countries, excluding few, to match
the population accepted for treatment in daily practice,
which enhances the external validity of the study findings.
Accordingly, the results of INCANT have high external
validity. In other words, they are generalisable to regular
treatment settings.
Our results confirm that MDFT is an effective programme
for treating substance abusing adolescents, especially ado-
lescents with high rates of externalising symptoms. One
could wonder how the effect of MDFT progresses. Does
this treatment programme first weaken externalising and
perhaps other co-morbid symptoms and, through this
pathway, then continue to reduce substance use and sub-
stance abuse? The available evidence suggests that MDFT
may do both: influencing substance use (and other prob-
lem behaviour) through a direct effect on this behaviour,
and diminishing substance use (problems) indirectly, by
affecting moderator variables such as externalising symp-
toms. And the reverse, i.e., direct and indirect influ-
ences of substance (ab)use on externalising symptoms
developing into for instance delinquency, is also true.
The evidence for the existence of both pathways has
been brought together in the Host-Provocation theory
[42]. Advanced statistical models confirm that substance
use and co-morbidity factors may interact in intricate
ways to elicit and strengthen unwanted behaviours in
adolescents [43].
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